Evidence map›Paper›PMID 41593097›Full record

Trial reportNature communications2026

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.

Tim Kong, Alex Mabry, Maureen Highkin, Anthony Z Wang, Jeremy Hoog, Zhanfang Guo, Adrian Gonzales-Gonzales, Shana Thomas, Yingduo Song, Feng Gao and 24 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01723774 (A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01723774 phase2active not recruitingnot on this map

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

TypeinterventionalSponsorWashington University School of MedicineRan2013 to 2026Enrolled84ConditionsBreast NeoplasmsArmsPD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Tim KongDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-3240-8989
Alex MabryDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-1635-8800
Maureen HighkinDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Anthony Z WangDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jeremy HoogDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Zhanfang GuoDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Adrian Gonzales-GonzalesDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Shana ThomasDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Yingduo SongDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0009-0002-9496-6270
Feng GaoDivision of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Mateusz OpyrchalDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-2454-7441
Lindsay PetersonDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Foluso AdemuyiwaDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-6766-2258
Julie MargenthalerSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Rebecca AftSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Katherine Glover-CollinsSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Leslie NehringDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Yu TaoDivision of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Souzan SanatiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Ian S HagemannDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-3855-9745
Fouad BoulosDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Matthew HoltBaylor College of Medicine, Houston, TX, USA.
Li DingDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-1517-2975
Wenge ZhuDepartment of Biochemistry and Molecular Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.ORCID http://orcid.org/0000-0001-9113-5020
Stephen T OhDivison of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-8564-5400
Jianxin WangDepartment of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-0998-4996
Agnieszka K WitkiewiczDepartment of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Erik S KnudsenDepartment of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-5130-5969
Ron BoseDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-1977-8894
Jason D WeberDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-1069-6983
Matthew GoetzDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Donald NorthfeltDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
Jingqin LuoDivision of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. jingqinluo@wustl.edu.ORCID http://orcid.org/0000-0003-2759-3072
Cynthia X MaDivison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. cynthiaxma@wustl.edu.ORCID http://orcid.org/0000-0002-8156-7492

Funding

Washington University Center for Cellular ImagingP30CA091842 · WASHINGTON UNIVERSITY · 2001 to 2025
$19.4M
Regulation of resistance to CDK4/6 inhibitor in breast cancerR01CA275904 · NCI · GEORGE WASHINGTON UNIVERSITY · 2023 to 2025
$1.3M
Antagonistic role of ARF and ADAR1 in triple-negative breast cancerR01CA262804 · WASHINGTON UNIVERSITY · 2025 to 2025
$418k
NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA262804NCI NIH HHS R01 CA275904U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) P30 CA91842
6 · The paper itself

Abstract

CDK4/6 inhibitors (CDK4/6i) improve outcomes for estrogen receptor (ER) positive/HER2-negative breast cancers (BCs), yet intrinsic and acquired resistance exist. Here, we evaluated anastrozole in combination with palbociclib (ANA/PAL) in the NeoPalAna Endocrine-Resistant cohort (NCT01723774). Thirty-four patients with clinical stage II/III ER + /HER2- BCs resistant to standard neoadjuvant endocrine therapy (on-treatment Ki67 > 10%) received neoadjuvant ANA/PAL, with serial biopsies analyzed. The primary endpoint, complete cell cycle arrest (CCCA; Ki67

Indexed as

AnastrozoleAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsPiperazinesPyridinesAdultAgedDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoadjuvant TherapyReceptors, EstrogenAnastrozoleBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesPyridinesReceptors, Estrogen

Identifiers

PMID41593097
PMCPMC12848104

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.